PGNY logo

Progyny (PGNY) Stock

Profile

Sector:

Healthcare

Country:

United States

IPO:

25 October 2019

Indexes:

Not included

Description:

Progyny, Inc. is an American company specializing in managing benefits in the field of reproductive health. Previously known as Auxogyn, Inc., the company changed its name to Progyny, Inc. in 2015. Progyny, Inc. was registered in 2008, with its headquarters located in New York, New York. The company offers the Smart Cycle treatment package, which includes all necessary diagnostic tests and access to the latest technologies (such as preimplantation genetic testing in the case of IVF treatment). Smart Cycle provides 17 different procedure packages that can be used independently or in combination, depending on the participant's needs. The company also offers Progyny Rx - a comprehensive pharmacy benefit solution that provides participants with access to medications needed during their treatment.

Events Calendar

Earnings

Next earnings date:

Feb 27, 2025

Recent quarterly earnings:

Nov 12, 2024

Recent annual earnings:

Feb 27, 2024
Dividend

Next ex-dividend date:

N/A

Recent ex-dividend date:

N/A
Splits

Next split:

N/A

Recent split:

N/A

Analyst ratings

Recent major analysts updates

02 Dec '24 JP Morgan
Neutral
14 Nov '24 Barclays
Overweight
13 Nov '24 Truist Securities
Hold
13 Nov '24 Canaccord Genuity
Hold
13 Nov '24 B of A Securities
Buy
01 Oct '24 Cantor Fitzgerald
Overweight
20 Sept '24 Canaccord Genuity
Hold
19 Sept '24 Truist Securities
Buy
19 Sept '24 Leerink Partners
Market Perform
19 Sept '24 Jefferies
Buy

Market Data

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Dividend

Profitability

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Efficiency

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Valuation

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Liquidity

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cash Flow

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Institutional Ownership

The Bottom Fishing Club: Progyny Reverses On Heavy Insider Buying
The Bottom Fishing Club: Progyny Reverses On Heavy Insider Buying
The Bottom Fishing Club: Progyny Reverses On Heavy Insider Buying
PGNY
seekingalpha.com30 December 2024

Progyny shares have plummeted nearly 80% from 2021's peak, but management optimism and insider buying in December signal a potential turnaround during 2025. PGNY's valuation is deeply discounted, with strong fundamentals: $235M in cash, no debt, and 9.64% in trailing free cash flow yield. The stock's rare accumulation/momentum pattern since September and potential short squeeze kicker make it an attractive Buy.

PGNY Stockholders: Robbins LLP is Investigating the Officers and Directors of Progyny, Inc. to Determine if They Breached Fiduciary Duties Owed to Shareholders
PGNY Stockholders: Robbins LLP is Investigating the Officers and Directors of Progyny, Inc. to Determine if They Breached Fiduciary Duties Owed to Shareholders
PGNY Stockholders: Robbins LLP is Investigating the Officers and Directors of Progyny, Inc. to Determine if They Breached Fiduciary Duties Owed to Shareholders
PGNY
prnewswire.com18 December 2024

SAN DIEGO , Dec. 18, 2024 /PRNewswire/ -- Shareholder rights law firm Robbins LLP is investigating Progyny, Inc. (NASDAQ: PGNY) to determine whether certain Progyny officers and directors violated securities laws and breached fiduciary duties to shareholders. Progyny, Inc., a benefits management company, specializes in fertility and family building benefits solutions for employers in the United States.

Robbins LLP Informs Progyny, Inc. Stockholders that it is Investigating the Officers and Directors of PGNY to Determine if They Breached Fiduciary Duties Owed to Shareholders
Robbins LLP Informs Progyny, Inc. Stockholders that it is Investigating the Officers and Directors of PGNY to Determine if They Breached Fiduciary Duties Owed to Shareholders
Robbins LLP Informs Progyny, Inc. Stockholders that it is Investigating the Officers and Directors of PGNY to Determine if They Breached Fiduciary Duties Owed to Shareholders
PGNY
globenewswire.com11 December 2024

SAN DIEGO, Dec. 11, 2024 (GLOBE NEWSWIRE) -- Shareholder rights law firm Robbins LLP is investigating Progyny, Inc. (NASDAQ: PGNY) to determine whether certain Progyny officers and directors violated securities laws and breached fiduciary duties to shareholders. Progyny, Inc., a benefits management company, specializes in fertility and family building benefits solutions for employers in the United States.

Johnson Fistel has Commenced an Investigation on Behalf of Progyny (PGNY) Shareholders
Johnson Fistel has Commenced an Investigation on Behalf of Progyny (PGNY) Shareholders
Johnson Fistel has Commenced an Investigation on Behalf of Progyny (PGNY) Shareholders
PGNY
globenewswire.com03 December 2024

SAN DIEGO, Dec. 03, 2024 (GLOBE NEWSWIRE) -- Johnson Fistel, LLP is investigating whether Progyny, Inc. (NASDAQ: PGNY) or others violated securities laws by misrepresenting or failing to timely disclose material adverse to investors. The investigation focuses on investors' losses and whether they may be recovered under federal securities laws.

Progyny: After A Terrible Year, I'm Out (Rating Downgrade)
Progyny: After A Terrible Year, I'm Out (Rating Downgrade)
Progyny: After A Terrible Year, I'm Out (Rating Downgrade)
PGNY
seekingalpha.com17 November 2024

I initially rated Progyny a "Buy" in late 2022, but 2024 has been disastrous, with a 60% stock drop and loss of Amazon as a client. Q3 2024 financials show minimal revenue growth, declining margins, and lower earnings per share, despite a strong balance sheet. Given management's struggles and increased competition, I no longer believe Progyny has a competitive advantage and have sold my shares.

Why Progyny Stock Crashed Today
Why Progyny Stock Crashed Today
Why Progyny Stock Crashed Today
PGNY
fool.com13 November 2024

Why Progyny Stock Crashed Today

Progyny, Inc. (PGNY) Q3 2024 Earnings Call Transcript
Progyny, Inc. (PGNY) Q3 2024 Earnings Call Transcript
Progyny, Inc. (PGNY) Q3 2024 Earnings Call Transcript
PGNY
seekingalpha.com12 November 2024

Progyny, Inc (NASDAQ:PGNY ) Q3 2024 Earnings Conference Call November 12, 2024 4:45 PM ET Company Participants James Hart - Investor Relations Peter Anevski - CEO Michael Sturmer - President Mark Livingston - CFO Conference Call Participants Anne Samuel - JPMorgan Allen Lutz - Bank of America Sarah James - Cantor Fitzgerald Michael Cherny - Leering Partners Glen Santangelo - Jefferies Jailendra Singh - Truist Securities Stephanie Davis - Barclays Scott Schoenhaus - KeyBanc Richard Close - Canaccord Genuity David Larsen - BTIG Operator Good day, and welcome to the Progyny, Inc. Third Quarter Earnings Conference Call. At this time all participants have been placed on listen-only mode.

Progyny (PGNY) Tops Q3 Earnings Estimates
Progyny (PGNY) Tops Q3 Earnings Estimates
Progyny (PGNY) Tops Q3 Earnings Estimates
PGNY
zacks.com12 November 2024

Progyny (PGNY) came out with quarterly earnings of $0.40 per share, beating the Zacks Consensus Estimate of $0.37 per share. This compares to earnings of $0.16 per share a year ago.

Progyny (PGNY) Client Retention Narrative Under Examination - Hagens Berman
Progyny (PGNY) Client Retention Narrative Under Examination - Hagens Berman
Progyny (PGNY) Client Retention Narrative Under Examination - Hagens Berman
PGNY
globenewswire.com08 November 2024

SAN FRANCISCO, Nov. 08, 2024 (GLOBE NEWSWIRE) -- Fertility benefits provider Progyny, Inc. (NASDAQ: PGNY) is under intense scrutiny following the unexpected announcement of a major client's departure.

Johnson Fistel has Commenced an Investigation on Behalf of Progyny (PGNY) Shareholders
Johnson Fistel has Commenced an Investigation on Behalf of Progyny (PGNY) Shareholders
Johnson Fistel has Commenced an Investigation on Behalf of Progyny (PGNY) Shareholders
PGNY
globenewswire.com08 November 2024

SAN DIEGO, Nov. 08, 2024 (GLOBE NEWSWIRE) -- Shareholder rights law firm Johnson Fistel, LLP is investigating whether Progyny, Inc. (NASDAQ: PGNY) or others violated securities laws by misrepresenting or failing to timely disclose material adverse to investors. The investigation focuses on investors' losses and whether they may be recovered under federal securities laws.

FAQ

  • What is the primary business of Progyny?
  • What is the ticker symbol for Progyny?
  • Does Progyny pay dividends?
  • What sector is Progyny in?
  • What industry is Progyny in?
  • What country is Progyny based in?
  • When did Progyny go public?
  • Is Progyny in the S&P 500?
  • Is Progyny in the NASDAQ 100?
  • Is Progyny in the Dow Jones?
  • When was Progyny's last earnings report?
  • When does Progyny report earnings?
  • Should I buy Progyny stock now?

What is the primary business of Progyny?

Progyny, Inc. is an American company specializing in managing benefits in the field of reproductive health. Previously known as Auxogyn, Inc., the company changed its name to Progyny, Inc. in 2015. Progyny, Inc. was registered in 2008, with its headquarters located in New York, New York. The company offers the Smart Cycle treatment package, which includes all necessary diagnostic tests and access to the latest technologies (such as preimplantation genetic testing in the case of IVF treatment). Smart Cycle provides 17 different procedure packages that can be used independently or in combination, depending on the participant's needs. The company also offers Progyny Rx - a comprehensive pharmacy benefit solution that provides participants with access to medications needed during their treatment.

What is the ticker symbol for Progyny?

The ticker symbol for Progyny is NASDAQ:PGNY

Does Progyny pay dividends?

No, Progyny does not pay dividends

What sector is Progyny in?

Progyny is in the Healthcare sector

What industry is Progyny in?

Progyny is in the Health Information Services industry

What country is Progyny based in?

Progyny is headquartered in United States

When did Progyny go public?

Progyny's initial public offering (IPO) was on 25 October 2019

Is Progyny in the S&P 500?

No, Progyny is not included in the S&P 500 index

Is Progyny in the NASDAQ 100?

No, Progyny is not included in the NASDAQ 100 index

Is Progyny in the Dow Jones?

No, Progyny is not included in the Dow Jones index

When was Progyny's last earnings report?

Progyny's most recent earnings report was on 12 November 2024

When does Progyny report earnings?

The next expected earnings date for Progyny is 27 February 2025

Should I buy Progyny stock now?

As of today, analysts generally recommend a 'Buy' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions